Lung Deposition and Inspiratory Flow Rate in Patients with Chronic Obstructive Pulmonary Disease Using Different Inhalation Devices: A Systematic Literature Review and Expert Opinion

References

• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi:10.1164/rccm.201701-0218PP
   PubMed Web of Science ®Google Scholar
• Collaborators GBDCRD. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706. doi:10.1016/S2213-2600(17)30293-X
   PubMed Web of Science ®Google Scholar
• Kostikas K, Clemens A, Patalano F. Prediction and prevention of exacerbations and mortality in patients with COPD. Expert Rev Respir Med. 2016;10(7):739–753. doi:10.1080/17476348.2016.1185371
   PubMed Web of Science ®Google Scholar
• Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235–245. doi:10.2147/CEOR.S34321
   PubMedGoogle Scholar
• Lopez-Campos JL, Quintana Gallego E, Carrasco Hernandez L. Status of and strategies for improving adherence to COPD treatment. Int J Chron Obstruct Pulmon Dis. 2019;14:1503–1515. doi:10.2147/COPD.S170848
   PubMed Web of Science ®Google Scholar
• Dal Negro RW. Dry powder inhalers and the right things to remember: a concept review. Multidiscip Respir Med. 2015;10(1):13. doi:10.1186/s40248-015-0012-5
   PubMedGoogle Scholar
• Area de asma de S, Area de enfermeria de S, Departamento de asma A. [SEPAR-ALAT consensus for inhaled therapies]. Arch Bronconeumol. 2013;49(Suppl 1):2–14. doi:10.1016/S0300-2896(13)70068-1
   PubMedGoogle Scholar
• Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019;15:461–472. doi:10.2147/TCRM.S160365
   PubMed Web of Science ®Google Scholar
• Garcia-Rio F, Soler-Cataluna JJ, Alcazar B, Viejo JL, Miravitlles M. Requirements, Strengths and Weaknesses of Inhaler Devices for COPD Patients from the Expert Prescribers’ Point of View: results of the EPOCA Delphi Consensus. COPD. 2017;14(6):573–580.
   PubMedGoogle Scholar
• Ghosh S, Ohar JA, Drummond MB. Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: implications for Dry Powder Inhalers. J Aerosol Med Pulm Drug Deliv. 2017;30(6):381–387. doi:10.1089/jamp.2017.1416
   PubMed Web of Science ®Google Scholar
• Virchow JC, Poli G, Herpich C, et al. Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler((R)) Device in Healthy Subjects, Asthmatic Patients, and COPD Patients. J Aerosol Med Pulm Drug Deliv. 2018;31(5):269–280. doi:10.1089/jamp.2016.1359
   PubMed Web of Science ®Google Scholar
• Lippmann M, Yeates DB, Albert RE. Deposition, retention, and clearance of inhaled particles. Br J Ind Med. 1980;37(4):337–362. doi:10.1136/oem.37.4.337
   PubMedGoogle Scholar
• Kafaei Shirmanesh Y, Jones MD. Physical ability of people with rheumatoid arthritis and age-sex matched controls to use four commonly prescribed inhaler devices. Respir Med. 2018;135:12–14. doi:10.1016/j.rmed.2017.12.014
   PubMed Web of Science ®Google Scholar
• Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013;26(3):174–179. doi:10.1089/jamp.2012.0987
   PubMed Web of Science ®Google Scholar
• Prime D, de Backer W, Hamilton M, et al. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA(R) Dry Powder Inhaler. J Aerosol Med Pulm Drug Deliv. 2015;28(6):486–497. doi:10.1089/jamp.2015.1224
   PubMed Web of Science ®Google Scholar
• Hamilton M, Leggett R, Pang C, Charles S, Gillett B, Prime D. In Vitro Dosing Performance of the ELLIPTA Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLungTM). J Aerosol Med Pulm Drug Deliv. 2015;28(6):498–506. doi:10.1089/jamp.2015.1225
   PubMed Web of Science ®Google Scholar
• Hira D, Koide H, Nakamura S, et al. Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using inspiratory flow meter for multi inhalation devices. PLoS One. 2018;13(2):e0193082. doi:10.1371/journal.pone.0193082
   PubMed Web of Science ®Google Scholar
• Howick J, Chalmers I, Glasziou P, et al. Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence (Background Document). 2011; https://www.cebm.net/index.aspx?o=5653. Accessed Nov 4, 2013, 2019.
   Google Scholar
• Ali M, Mazumder MK, Martonen TB. Measurements of electrodynamic effects on the deposition of MDI and DPI aerosols in a replica cast of human oral-pharyngeal-laryngeal airways. J Aerosol Med Pulm Drug Deliv. 2009;22(1):35–44. doi:10.1089/jamp.2007.0637
   PubMed Web of Science ®Google Scholar
• Al-Showair RAM, Tarsin WY, Assi KH, Pearson SB, Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007;101(11):2395–2401. doi:10.1016/j.rmed.2007.06.008
   PubMed Web of Science ®Google Scholar
• Bagherisadeghi G, Larhrib EH, Chrystyn H. Real life dose emission characterization using COPD patient inhalation profiles when they inhaled using a fixed dose combination (FDC) of the medium strength Symbicort Turbuhaler. Int J Pharm. 2017;522(1–2):137–146. doi:10.1016/j.ijpharm.2017.02.057
   PubMedGoogle Scholar
• Borgstrom L, Asking L, Lipniunas P. An in vivo and in vitro comparison of two powder inhalers following storage at hot/humid conditions. J Aerosol Med. 2005;18(3):304–310. doi:10.1089/jam.2005.18.304
   PubMedGoogle Scholar
• Canonica GW, Arp J, Keegstra JR, Chrystyn H. Spiromax, a New Dry Powder Inhaler: dose Consistency under Simulated Real-World Conditions. J Aerosol Med Pulm Drug Deliv. 2015;28(5):309–319. doi:10.1089/jamp.2015.1216
   PubMed Web of Science ®Google Scholar
• Chapman KR, Fogarty CM, Peckitt C, et al. Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:353‐363. doi:10.2147/COPD.S18529
   PubMed Web of Science ®Google Scholar
• Cheng YS, Fu CS, Yazzie D, Zhou Y. Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica. J Aerosol Med. 2001;14(2):255–266. doi:10.1089/08942680152484180
   PubMedGoogle Scholar
• Chodosh S, Flanders JS, Kesten S, Serby CW, Hochrainer D, Witek TJ. Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med. 2001;14(3):309–315. doi:10.1089/089426801316970268
   PubMedGoogle Scholar
• Ciciliani AM, Wachtel H, Langguth P. Comparing Respimat® Soft Mist™ Inhaler and DPI Aerosol Deposition by Combined In Vitro Measurements and CFD Simulations. Respir Drug Delivery. 2014;453–456.
   PubMedGoogle Scholar
• Ciciliani AM, Wachtel H, Heussel CP, Langguth P. Evaluation of Respimat®Soft Mist™ Inhaler Based on In Vitro Measurements and CFD Simulations. Respir Drug Delivery Eur. 2015;1–5.
   Google Scholar
• Colthorpe P, Voshaar T, Kieckbusch T, Cuoghi E, Jauernig J. Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium. J Drug Assess. 2013;2(1):11–16. doi:10.3109/21556660.2013.766197
   PubMedGoogle Scholar
• DeHaan WH, Finlay WH. In vitro monodisperse aerosol deposition in a mouth and throat with six different inhalation devices. J Aerosol Med. 2001;14(3):361–367. doi:10.1089/089426801316970321
   PubMedGoogle Scholar
• Gillen M, Forte P, Svensson JO, et al. Effect of a spacer on total systemic and lung bioavailability in healthy volunteers and in vitro performance of the Symbicort (budesonide/formoterol) pressurized metered dose inhaler. Pulm Pharmacol Ther. 2018;52:7–17. doi:10.1016/j.pupt.2018.08.001
   PubMed Web of Science ®Google Scholar
• Jogi R, Lahelma S, Vahteristo M, Happonen A, Haikarainen J. In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial. J Aerosol Med Pulm Drug Deliv. 2019;32(2):88–98. doi:10.1089/jamp.2018.1463
   PubMed Web of Science ®Google Scholar
• Melchor R, Biddiscombe MF, Mak VH, Short MD, Spiro SG. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax. 1993;48(5):506–511. doi:10.1136/thx.48.5.506
   PubMed Web of Science ®Google Scholar
• Meyer T, Brand P, Ehlich H, et al. Deposition of Foradil P in human lungs: comparison of in vitro and in vivo data. J Aerosol Med. 2004;17(1):43–49. doi:10.1089/089426804322994451
   PubMedGoogle Scholar
• Rahmatalla MF, Zuberbuhler PC, Lange CF, Finlay WH. In vitro effect of a holding chamber on the mouth-throat deposition of QVAR (hydrofluoroalkane-beclomethasone dipropionate). J Aerosol Med. 2002;15(4):379–385. doi:10.1089/08942680260473452
   PubMedGoogle Scholar
• Weers J, Ung K, Le J, et al. Dose emission characteristics of placebo PulmoSphere particles are unaffected by a subject’s inhalation maneuver. J Aerosol Med Pulm Drug Deliv. 2013;26(1):56–68. doi:10.1089/jamp.2012.0973
   PubMed Web of Science ®Google Scholar
• Wilson R, Templeton A, Leemereise C, et al. Safety, Tolerability, and Pharmacokinetics of a New Formulation of Nemiralisib Administered via a Dry Powder Inhaler to Healthy Individuals. Clin Ther. 2019;41(6):1214–1220. doi:10.1016/j.clinthera.2019.04.008
   PubMed Web of Science ®Google Scholar
• Worth Longest P, Hindle M. Evaluation of the Respimat Soft Mist Inhaler using a concurrent CFD and in vitro approach. J Aerosol Med Pulm Drug Deliv. 2009;22(2):99–112. doi:10.1089/jamp.2008.0708
   PubMed Web of Science ®Google Scholar
• Yang TT, Li S, Wyka B, Kenyon D. Drug delivery performance of the mometasone furoate dry powder inhaler. J Aerosol Med. 2001;14(4):487–494. doi:10.1089/08942680152744695
   PubMedGoogle Scholar
• Zhang Y, Gilbertson K, Finlay WH. In vivo-in vitro comparison of deposition in three mouth-throat models with Qvar and Turbuhaler inhalers. J Aerosol Med. 2007;20(3):227–235. doi:10.1089/jam.2007.0584
   PubMedGoogle Scholar
• Haidl P, Heindl S, Siemon K, Bernacka M, Cloes RM. Inhalation device requirements for patients’ inhalation maneuvers. Respir Med. 2016;118:65–75. doi:10.1016/j.rmed.2016.07.013
   PubMed Web of Science ®Google Scholar
• Aalto E, Havu M, Kotaniemi J, et al. Comparison of terbutaline Turbuhaler and albuterol chlorofluorocarbon (CFC) inhaler in middle-aged and elderly patients with obstructive lung disease. Ann Allergy. 1992;69(1):33‐36.
   PubMedGoogle Scholar
• Broeders ME, Molema J, Hop WC, Folgering HT. Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction. J Aerosol Med. 2003;16(2):131‐141. doi:10.1089/089426803321919898
   PubMedGoogle Scholar
• Broeders MEAC, Molema J, Hop WCJ, Vermue NA, Folgering HTM. The course of inhalation profiles during an exacerbation of obstructive lung disease. Respir Med. 2004;98(12):1173–1179. doi:10.1016/j.rmed.2004.04.010
   PubMed Web of Science ®Google Scholar
• Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderly COPD patients; time for re-evaluation? Age Ageing. 2007;36(2):213–218. doi:10.1093/ageing/afl174
   PubMed Web of Science ®Google Scholar
• Newman SP, Pitcairn GR, Adkin DA, Vidgren MT, Silvasti M. Comparison of beclomethasone dipropionate delivery by easyhaler dry powder inhaler and pMDI plus large volume spacer. J Aerosol Med. 2001;14(2):217–225. doi:10.1089/08942680152484144
   PubMedGoogle Scholar
• Brand P, Hederer B, Austen G, Dewberry H, Meyer T. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis. 2008;3(4):763‐770.
   PubMedGoogle Scholar
• Newman SP, Brown J, Steed KP, Reader SJ, Kladders H. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest. 1998;113(4):957–963. doi:10.1378/chest.113.4.957
   PubMed Web of Science ®Google Scholar
• Steed KP, Towse LJ, Freundc B, Newman SP. Lung and oropharyngeal depositions of fenoterol hydrobromide delivered 1 from the prototype III hand-held multidose Respimat nebuliser. Eur J Pharm. 1997;5(2):55–61. doi:10.1016/S0928-0987(96)00016-4
   Web of Science ®Google Scholar
• Stuart BO. Deposition and clearance of inhaled particles. Environ Health Perspect. 1984;55:369–390. doi:10.1289/ehp.8455369
   PubMed Web of Science ®Google Scholar
• Lange CF, Finlay WH. Overcoming the adverse effect of humidity in aerosol delivery via pressurized metered-dose inhalers during mechanical ventilation. Am J Respir Crit Care Med. 2000;161(5):1614–1618. doi:10.1164/ajrccm.161.5.9909032
   PubMed Web of Science ®Google Scholar
• Horváth A, Balásházy I, Tomisa G, Farkas Á. Significance of breath-hold time in dry powder aerosol drug therapy of COPD patients. Eur J Pharm Sci. 2017;104:145–149. doi:10.1016/j.ejps.2017.03.047
   PubMed Web of Science ®Google Scholar
• Broeders ME, Molema J, Hop WC, Vermue NA, Folgering HT. The course of inhalation profiles during an exacerbation of obstructive lung disease. Respir Med. 2004;98(12):1173–1179.
   PubMed Web of Science ®Google Scholar
• Newman SP, Moren F, Pavia D, Little F, Clarke SW. Deposition of pressurized suspension aerosols inhaled through extension devices. Am Rev Respir Dis. 1981;124(3):317–320. doi:10.1164/arrd.1981.124.3.317
   PubMedGoogle Scholar
• Newman SP, Clarke SW. Therapeutic aerosols 1–physical and practical considerations. Thorax. 1983;38(12):881–886. doi:10.1136/thx.38.12.881
   PubMed Web of Science ®Google Scholar
• De Backer W, Devolder A, Poli G, et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv. 2010;23(3):137–148. doi:10.1089/jamp.2009.0772
   PubMed Web of Science ®Google Scholar
• Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest. 2002;122(2):510–516. doi:10.1378/chest.122.2.510
   PubMed Web of Science ®Google Scholar
• Taylor RG, Pavia D, Agnew JE, et al. Effect of four weeks’ high dose ipratropium bromide treatment on lung mucociliary clearance. Thorax. 1986;41(4):295‐300. doi:10.1136/thx.41.4.295
   Web of Science ®Google Scholar
• Vidgren M, Karkkainen A, Karjalainen P. Effect of extension devices on the drug deposition from inhalation aerosols. Int J Pharm. 1987;39:1107–1111. doi:10.1016/0378-5173(87)90204-3
   Web of Science ®Google Scholar
• Richards J, Hirst P, Pitcairn G, et al. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J Aerosol Med. 2001;14(2):197–208. doi:10.1089/08942680152484126
   PubMedGoogle Scholar
• Ashworth HL, Wilson CG, Sims EE, Wotton PK, Hardy JG. Delivery of propellant soluble drug from a metered dose inhaler. Thorax. 1991;46(4):245–247. doi:10.1136/thx.46.4.245
   PubMed Web of Science ®Google Scholar
• Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev. 2013;(9):CD000052.
   PubMed Web of Science ®Google Scholar
• Newman SP, Weisz AW, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax. 1991;46(10):712–716. doi:10.1136/thx.46.10.712
   PubMed Web of Science ®Google Scholar
• Leach C. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol. 1999;104(6):S250–252. doi:10.1016/S0091-6749(99)70041-2
   PubMed Web of Science ®Google Scholar
• Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998;12(6):1346–1353. doi:10.1183/09031936.98.12061346
   PubMed Web of Science ®Google Scholar
• Haussermann S, Acerbi D, Brand P, et al. Lung deposition of formoterol HFA (Atimos/Forair) in healthy volunteers, asthmatic and COPD patients. J Aerosol Med. 2007;20(3):331–341. doi:10.1089/jam.2007.0613
   PubMedGoogle Scholar
• Kappeler D, Sommerer K, Kietzig C, et al. Pulmonary deposition of fluticasone propionate/formoterol in healthy volunteers, asthmatics and COPD patients with a novel breath-triggered inhaler. Respir Med. 2018;138:107–114. doi:10.1016/j.rmed.2018.03.029
   PubMed Web of Science ®Google Scholar
• Taburet AM, Schmit B. Pharmacokinetic optimisation of asthma treatment. Clin Pharmacokinet. 1994;26(5):396–418. doi:10.2165/00003088-199426050-00006
   PubMed Web of Science ®Google Scholar
• Fernandez Tena A, Casan Clara P. Deposition of inhaled particles in the lungs. Arch Bronconeumol. 2012;48(7):240–246. doi:10.1016/j.arbr.2012.02.006
   PubMed Web of Science ®Google Scholar
• Agertoft L, Pedersen S. Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children. Am J Respir Crit Care Med. 2003;168(7):779–782. doi:10.1164/rccm.200302-200OC
   PubMed Web of Science ®Google Scholar
• Delvadia R, Hindle M, Longest PW, Byron PR. In vitro tests for aerosol deposition II: iVIVCs for different dry powder inhalers in normal adults. J Aerosol Med Pulm Drug Deliv. 2013;26(3):138–144. doi:10.1089/jamp.2012.0975
   PubMed Web of Science ®Google Scholar
• Hirst PH, Bacon RE, Pitcairn GR, Silvasti M, Newman SP. A comparison of the lung deposition of budesonide from Easyhaler, Turbuhaler and pMDI plus spacer in asthmatic patients. Respir Med. 2001;95(9):720–727. doi:10.1053/rmed.2001.1107
   PubMed Web of Science ®Google Scholar
• Leach CL, Bethke TD, Boudreau RJ, et al. Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers. J Aerosol Med. 2006;19(2):117–126. doi:10.1089/jam.2006.19.117
   PubMedGoogle Scholar
• Ciciliani AM, Langguth P, Wachtel H. In vitro dose comparison of Respimat((R)) inhaler with dry powder inhalers for COPD maintenance therapy. Int J Chron Obstruct Pulmon Dis. 2017;12:1565–1577. doi:10.2147/COPD.S115886
   PubMed Web of Science ®Google Scholar
• Vidgren M, KWkkiinen A, Karjalainen P, Paronen P, Nuutinen J. Effect of powder inhaler design on drug in the respiratory tract. Int J Pharm. 1988;42:211–216. doi:10.1016/0378-5173(88)90177-9
   Web of Science ®Google Scholar
• Mariotti F, Sergio F, Acerbi D, Meyer T, Herpich C. Lung Deposition of the Extrafine Dry Powder Fixed Combination Beclomethasone Dipropionate Plus Formoterol Fumarate via the NEXT DPI^® in Healthy Subjects, Asthmatic and COPD Patients. Amsterdam: RS Annual Congress; 2011.
   Google Scholar
• Newman SP, Moren F, Trofast E, Talaee N, Clarke SW. Deposition and clinical efficacy of terbutaline sulphate from Turbuhaler, a new multi-dose powder inhaler. Eur Respir J. 1989;2(3):247–252.
   PubMed Web of Science ®Google Scholar
• Thorsson L, Edsbacker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler® is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J. 1994;7(10):1839–1844. doi:10.1183/09031936.94.07101839
   PubMed Web of Science ®Google Scholar
• Burnell PK, Small T, Doig S, Johal B, Jenkins R, Gibson GJ. Ex-vivo product performance of DiskusTMand TurbuhalerTMinhalers using inhalation profiles from patients with severe chronic obstructive pulmonary disease. Respir Med. 2001;95(5):324‐330. doi:10.1053/rmed.2001.1044
   PubMed Web of Science ®Google Scholar
• Dolovich MA. Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung. Respir Care. 2000;45(6):597–608.
   PubMedGoogle Scholar
• Horváth A, Farkas Á, Szipőcs A, Tomisa G, Szalai Z, Gálffy G. Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients. Eur J Pharm Sci. 2020;154:105508.
   PubMed Web of Science ®Google Scholar
• Brand P, Hederer B, Austen G, Dewberry H, Meyer T. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis. 2008;3(4):763–770.
   PubMedGoogle Scholar
• Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med. 2005;18(3):264–272.
   PubMedGoogle Scholar
• Newman SP, Newhouse MT. Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. J Aerosol Med. 1996;9(1):55–70.
   PubMedGoogle Scholar
• Wachtel H, Kattenbeck S, Dunne S, Disse B. The Respimat® Development Story: patient-Centered Innovation. Pulmonary Therapy. 2017;3(1):19–30.
   Google Scholar
• Iwanaga T, Kozuka T, Nakanishi J, et al. Aerosol Deposition of Inhaled Corticosteroids/Long-Acting β2-Agonists in the Peripheral Airways of Patients with Asthma Using Functional Respiratory Imaging, a Novel Imaging Technology. Pulmonary Therapy. 2017;3(1):219–231.
   Google Scholar
• Altshuler BYL, Palmes ED. Aerosols deposition in the human respiratory tract. Arch Environ Health. 1957;15:292–303.
   Google Scholar
• Hochrainer D, Holz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005;18(3):273–282.
   PubMedGoogle Scholar
• Zierenberg B. Optimizing the in vitro performance of Respimat. J Aerosol Med. 1999;12(Suppl 1):S19–24.
   PubMedGoogle Scholar
• Tamura G. Comparison of the aerosol velocity of Respimat(R) soft mist inhaler and seven pressurized metered dose inhalers. Allergol Int. 2015;64(4):390–392.
   PubMed Web of Science ®Google Scholar
• Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet. 2011;377(9770):1032–1045.
   PubMed Web of Science ®Google Scholar
• Scichilone N, Spatafora M, Battaglia S, Arrigo R, Benfante A, Bellia V. Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations. J Asthma Allergy. 2013;6:11–21.
   PubMedGoogle Scholar
• Janssens HM, Krijgsman A, Verbraak TF, Hop WC, de Jongste JC, Tiddens HA. Determining factors of aerosol deposition for four pMDI-spacer combinations in an infant upper airway model. J Aerosol Med. 2004;17(1):51–61.
   PubMedGoogle Scholar
• Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med. 2005;172(12):1497–1504.
   PubMed Web of Science ®Google Scholar
• Newman SP, Steed KP, Reader SJ, Hooper G, Zierenberg B. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci. 1996;85(9):960–964.
   PubMed Web of Science ®Google Scholar
• Newman SP, Sutton DJ, Segarra R, Lamarca R, de Miquel G. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration. 2009;78(3):322–328.
   PubMed Web of Science ®Google Scholar
• Franssen FM, Wouters EF, Schols AM. The contribution of starvation, deconditioning and ageing to the observed alterations in peripheral skeletal muscle in chronic organ diseases. Clin Nutr. 2002;21(1):1–14.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Couser JI, Celli BR. Factors influencing ventilatory muscle recruitment in patients with chronic airflow obstruction. Am Rev Respir Dis. 1990;142(2):276–282.
   PubMedGoogle Scholar
• Newhouse M, Sanchis J, Bienenstock J. Lung defense mechanisms (first of two parts). N Engl J Med. 1976;295(18):990–998.
   PubMed Web of Science ®Google Scholar
• Dolovich M, Ruffin RE, Roberts R, Newhouse MT. Optimal delivery of aerosols from metered dose inhalers. Chest. 1981;80(6 Suppl):911–915.
   PubMed Web of Science ®Google Scholar
• Al-Showair RA, Tarsin WY, Assi KH, Pearson SB, Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007;101(11):2395–2401.
   PubMed Web of Science ®Google Scholar
• Janssens W, VandenBrande P, Hardeman E, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31(1):78–83. doi:10.1183/09031936.00024807
   PubMed Web of Science ®Google Scholar
• Kawamatawong T, Khiawwan S, Pornsuriyasak P. Peak inspiratory flow rate measurement by using In-Check DIAL for the different inhaler devices in elderly with obstructive airway diseases. J Asthma Allergy. 2017;10:17–21. doi:10.2147/JAA.S127580
   PubMed Web of Science ®Google Scholar
• Seheult JN, Costello S, Tee KC, et al. Investigating the relationship between peak inspiratory flow rate and volume of inhalation from a DiskusTM Inhaler and baseline spirometric parameters: a cross-sectional study. SpringerPlus. 2014;3(101597967):496. doi:10.1186/2193-1801-3-496
   PubMedGoogle Scholar
• Taylor TE, Lacalle Muls H, Costello RW, Reilly RB. Estimation of inhalation flow profile using audio-based methods to assess inhaler medication adherence. PLoS One. 2018;13(1):e0191330. doi:10.1371/journal.pone.0191330
   PubMed Web of Science ®Google Scholar
• Warren S, Taylor G, Smith J, Buck H, Parry-Billings M. Gamma scintigraphic evaluation of a novel budesonide dry powder inhaler using a validated radiolabeling technique. J Aerosol Med. 2002;15(1):15–25. doi:10.1089/08942680252908548
   PubMedGoogle Scholar
• Weiner P, Weiner M. Inspiratory muscle training may increase peak inspiratory flow in chronic obstructive pulmonary disease. Respir Int Rev Thoracic Dis. 2006;73(2):151‐156. doi:10.1159/000088095
   Google Scholar
• Azouz W, Chetcuti P, Hosker H, Saralaya D, Chrystyn H. Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax and Turbuhaler devices: a randomised, cross-over study. BMC Pulm Med. 2015;15(100968563):47. doi:10.1186/s12890-015-0043-x
   PubMedGoogle Scholar
• Anderson P. Use of Respimat Soft Mist inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2006;1(3):251–259. doi:10.2147/copd.2006.1.3.251
   PubMedGoogle Scholar
• Terry PD, Dhand R. Inhalation Therapy for Stable COPD: 20 Years of GOLD Reports. Adv Ther. 2020;37(5):1812–1828. doi:10.1007/s12325-020-01289-y
   PubMed Web of Science ®Google Scholar
• Lavorini F, Corrigan CJ, Barnes PJ, et al. Retail sales of inhalation devices in European countries: so much for a global policy. Respir Med. 2011;105(7):1099–1103. doi:10.1016/j.rmed.2011.03.012
   PubMed Web of Science ®Google Scholar
• Sanchis J, Gich I, Pedersen S. Aerosol Drug Management Improvement T Systematic Review of Errors in Inhaler Use: has Patient Technique Improved Over Time? Chest. 2016;150(2):394–406. doi:10.1016/j.chest.2016.03.041
   PubMed Web of Science ®Google Scholar
• Carstairs JR, Nimmo AJ, Barnes PJ. Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. Am Rev Respir Dis. 1985;132(3):541–547. doi:10.1164/arrd.1985.132.3.541
   PubMedGoogle Scholar
• Mak JC, Barnes PJ. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. Am Rev Respir Dis. 1990;141(6):1559–1568. doi:10.1164/ajrccm/141.6.1559
   PubMed Web of Science ®Google Scholar